CareSignal Launches CareSignal AI to Tackle the Issues Associated with Patient Disengagement

CareSignal AI utilizes only the data and metadata created by each patient's interactions with the white-labeled CareSignal program, whether for heart failure, COPD, depression, opioid management, or dozens of other condition-specific programs.

FREMONT, CA: CareSignal that offers Deviceless Remote Patient Monitoring approved by over ten peer-reviewed publications to provide an industry-leading clinical and financial return, announced the launch of CareSignal AI to address one among the most crucial areas in healthcare: patient disengagement.

Any payer or integrated delivery network (IDN) that has rolled out a patient-focused digital application recognizes that rapid drop-off soon kills clinical outcomes and, thereby, reduces ROI. Unlike other AI solutions, CareSignal AI proactively acts on data to re-engage patients and predicts disengagement before it happens with accuracy and recall of over 80 percent.

"This application of artificial intelligence to create value by preventing patient disengagement represents a major step toward predictive and preventive value-based care for CareSignal," said Blake Marggraff, co-founder and CEO of CareSignal. "CareSignal AI is already bringing clinical and financial benefit to our current partners; our data strategy will enable increasingly differentiated and defensible value as we grow. Above all, on our march to become the standard of care, CareSignal AI serves the organizations and patients who have the most to gain."

Using a composite of various predictive models, CareSignal AI leverages over 80 features to predict disengagement risk that starts as soon as a week after a patient enrolls. Trained patient engagement specialists then perform outreach, successfully re-engaging more than half of the patients who would have otherwise fallen off and likely experienced bad health outcomes.

CareSignal AI utilizes only the data and metadata created by each patient's interactions with the white-labeled CareSignal program, whether for heart failure, COPD, depression, opioid management, or dozens of other condition-specific programs. It works for all new client-partners, promptly and without any pass-through costs. Best of all, the client-partner experiences no change in workflow.

"CareSignal AI is based on almost 7 million patient-days of data and metadata," said Evan Huang, co-founder and chief developer of CareSignal. "That's equivalent to what a care manager would see over 16 lifetimes of work. And because the average accuracy and recall of the predictive models are so high, all without relying on any paid data sources, the value of the technology translates directly back to our client-partners. At the end of the day, AI-informed re-engagement is more than 11 times more effective and efficient than manual outreach. I am excited to bring a real application of AI to healthcare, and this is only the beginning."